[ad_1]
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)) has announced the release of limited doses of the generic version of EpiPen approved by the FDA, for the treatment of life-threatening allergies.
EpiPen is the flagship drug of Mylan, Teva's pharmaceutical rival. Mylan acquired the drug from Merck KGaA in 2007. Teva has long awaited the approval of a generic EpiPen by the FDA after the rejection of its 2016 application on the grounds that a generic version could not to be launched only in 2017. In the end year. EpiPen has had a controversial history with serious complaints two years ago regarding price increases and a settlement of $ 465 million in a compromise agreement with the Medicaid government insurance program for incorrect clbadification.
RELATED ARTICLES
Teva markets EpiPen as an auto-injector dosed at 0.3 mg. The publicly available wholesale acquisition cost (WAC) for the product is $ 300.
Brendan O. Grady, Executive Vice President and Head of Commercial Activities for North America at Teva, said: "We are delighted to provide access to epinephrine by injection (auto-injector ) to patients likely to undergo additional refueling emergencies in 2019. "
Posted by Globes, Israel business news – www.globes.co.il – November 28, 2018
© Copyright Globes Publisher Itonut (1983) Ltd. 2018
[ad_2]
Source link
